Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher dendritic cell vaccine as maintenance after chemotherapy in mesothelioma
2017-001774-41Phase 2Completed
- Sponsor
- Amphera B.V.
- Start
- Sep 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma and mesothelioma comparing MesoPher + best supportive care with Best supportive care alone (2 arms). Primary endpoint: overall survival. Started Sep 2017; status: completed.
02
Drugs
MesoPher
03
Conditions
pleural mesotheliomamesothelioma
Beyond the preview
Go deeper on 2017-001774-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001774-41.